Koning
A better way of breast imaging
Analytics
Raised: $512,976
Aggregate Commitments $
StartEngine
08/01/2022
12/30/2022
$9,997
$2,898,856
$489
Equity - Common
RegCF
Series C
$5.69
$230,180,296
Rolling Commitments $
Active
12/09/2022
21
5,131%
18%
$3,946
361
Norcross, Georgia
Healthcare & Pharmaceuticals
Medtech
B2B
Medium
High
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$357,779 |
$3,089,624 |
|
COGS |
$153,022 |
$417,340 |
|
Tax |
$65 |
$5,085 |
| ||
| ||
|
Net Income |
$-4,869,465 |
$-1,135,429 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$522,412 |
$1,099,408 |
|
Accounts Receivable |
$322,892 |
$777,636 |
|
Total Assets |
$26,507,126 |
$27,843,270 |
|
Short-Term Debt |
$3,768,501 |
$4,358,049 |
|
Long-Term Debt |
$5,355,334 |
$5,198,730 |
|
Total Liabilities |
$9,123,835 |
$9,556,779 |
Upgrade to gain access
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Ratings 
Wall Street has Morningstar, S&P, and Bloomberg
The equity crowdfunding market has KingsCrowd.
Analyst Report
Koning’s machines can reliably detect stage 0 and stage 1 cancers. Just how significant is this? Detecting breast cancer at stages 0 or 1 gives patients a 99% five-year survival rate. Its imaging technology can also detect small calcifications and small tumors in patients with small or dense breasts — something current mammograms struggle with. Calcifications, by the way, are often an early indicator of breast disease.
This changes the game. Mammography has ruled the industry for 60 years. While flawed, it was — for its time — the best technology available. That’s no longer the case.